245 related articles for article (PubMed ID: 21249149)
1. The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis.
Secondini C; Wetterwald A; Schwaninger R; Thalmann GN; Cecchini MG
PLoS One; 2011 Jan; 6(1):e16078. PubMed ID: 21249149
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
3. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.
Schwaninger R; Rentsch CA; Wetterwald A; van der Horst G; van Bezooijen RL; van der Pluijm G; Löwik CW; Ackermann K; Pyerin W; Hamdy FC; Thalmann GN; Cecchini MG
Am J Pathol; 2007 Jan; 170(1):160-75. PubMed ID: 17200191
[TBL] [Abstract][Full Text] [Related]
4. Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development.
Okamoto M; Murai J; Yoshikawa H; Tsumaki N
J Bone Miner Res; 2006 Jul; 21(7):1022-33. PubMed ID: 16813523
[TBL] [Abstract][Full Text] [Related]
5. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration.
Feeley BT; Liu NQ; Conduah AH; Krenek L; Roth K; Dougall WC; Huard J; Dubinett S; Lieberman JR
J Bone Miner Res; 2006 Oct; 21(10):1571-80. PubMed ID: 16995812
[TBL] [Abstract][Full Text] [Related]
6. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism.
Dai J; Keller J; Zhang J; Lu Y; Yao Z; Keller ET
Cancer Res; 2005 Sep; 65(18):8274-85. PubMed ID: 16166304
[TBL] [Abstract][Full Text] [Related]
7. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
[TBL] [Abstract][Full Text] [Related]
8. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
9. The BMP antagonist Noggin is produced by osteoblasts in response to the presence of prostate cancer cells.
AlShaibi HF; Ahmed F; Buckle C; Fowles ACM; Awlia J; Cecchini MG; Eaton CL
Biotechnol Appl Biochem; 2018 May; 65(3):407-418. PubMed ID: 28981962
[TBL] [Abstract][Full Text] [Related]
10. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer.
Haudenschild DR; Palmer SM; Moseley TA; You Z; Reddi AH
Cancer Res; 2004 Nov; 64(22):8276-84. PubMed ID: 15548695
[TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.
Virk MS; Alaee F; Petrigliano FA; Sugiyama O; Chatziioannou AF; Stout D; Dougall WC; Lieberman JR
Bone; 2011 Mar; 48(3):578-87. PubMed ID: 21073986
[TBL] [Abstract][Full Text] [Related]
12. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.
Li ZG; Yang J; Vazquez ES; Rose D; Vakar-Lopez F; Mathew P; Lopez A; Logothetis CJ; Lin SH; Navone NM
Oncogene; 2008 Jan; 27(5):596-603. PubMed ID: 17700537
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein.
Dai J; Kitagawa Y; Zhang J; Yao Z; Mizokami A; Cheng S; Nör J; McCauley LK; Taichman RS; Keller ET
Cancer Res; 2004 Feb; 64(3):994-9. PubMed ID: 14871830
[TBL] [Abstract][Full Text] [Related]
14. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases.
Larson SR; Zhang X; Dumpit R; Coleman I; Lakely B; Roudier M; Higano CS; True LD; Lange PH; Montgomery B; Corey E; Nelson PS; Vessella RL; Morrissey C
Prostate; 2013 Jun; 73(9):932-40. PubMed ID: 23334979
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms.
Dai J; Hall CL; Escara-Wilke J; Mizokami A; Keller JM; Keller ET
Cancer Res; 2008 Jul; 68(14):5785-94. PubMed ID: 18632632
[TBL] [Abstract][Full Text] [Related]
16. Regarding the article "Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions", by Feeley et al.
Friedlaender GE
Bone; 2006 Sep; 39(3):666; author reply 667. PubMed ID: 16774855
[No Abstract] [Full Text] [Related]
17. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
Ye L; Lewis-Russell JM; Kynaston H; Jiang WG
J Urol; 2007 Sep; 178(3 Pt 1):1086-91. PubMed ID: 17644136
[TBL] [Abstract][Full Text] [Related]
18. Contextual effect of repression of bone morphogenetic protein activity in prostate cancer.
Pham LK; Liang M; Adisetiyo HA; Liao CP; Cohen MB; Tahara SM; Frenkel B; Kasahara N; Roy-Burman P
Endocr Relat Cancer; 2013 Dec; 20(6):861-74. PubMed ID: 24042462
[TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of osteolytic bone metastases.
Guise TA
Cancer; 2000 Jun; 88(12 Suppl):2892-8. PubMed ID: 10898330
[TBL] [Abstract][Full Text] [Related]
20. Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease.
Straign DM; Ihle CL; Provera MD; Owens P
Front Endocrinol (Lausanne); 2021; 12():769316. PubMed ID: 34956082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
